Comparative Pharmacology
Head-to-head clinical analysis: SERPASIL ESIDRIX 1 versus TRIBENZOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SERPASIL ESIDRIX 1 versus TRIBENZOR.
SERPASIL-ESIDRIX #1 vs TRIBENZOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
TRIBENZOR is a fixed-dose combination of olmesartan, an angiotensin II receptor blocker that inhibits the vasopressor and aldosterone-secreting effects of angiotensin II, and amlodipine, a dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in vasodilation.
1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.
Tribenzor (olmesartan medoxomil/amlodipine/hydrochlorothiazide) is available in fixed-dose combinations. Typical adult dose: one tablet orally once daily. Starting dose depends on prior antihypertensive therapy; maximum recommended dose is olmesartan 40 mg/amlodipine 10 mg/HCTZ 25 mg per day.
None Documented
None Documented
Reserpine: 50-100 hours (terminal); clinical effects persist due to irreversible adrenergic neuron blockade. Hydrochlorothiazide: 6-15 hours (terminal).
Terminal half-life 9-11 hours; supports once-daily dosing
Reserpine: renal (30% as metabolites, <1% unchanged), fecal (60% as metabolites). Hydrochlorothiazide: renal (>95% unchanged).
Renal: 50-60% as unchanged drug and metabolites; Biliary/Fecal: 40-50%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination